Soy-isoflavone-enriched foods and markers of lipid and glucose metabolism in postmenopausal women:: interactions with genotype and equol production
Soy-isoflavone-enriched foods and markers of lipid and glucose metabolism in postmenopausal women:: interactions with genotype and equol production
复制标题
DOI：
10.1093/ajcn.83.3.592
复制
发表时间：
2006-03-01
影响因子：
7.1
通讯作者：
Williams, CM
中科院分区：
文献类型：
--
作者：
Hall, WL;Vafeiadou, K;Williams, CM
背景：大豆食品的降胆固醇作用已经得到证实，并且有人认为异黄酮是造成这种效果的原因。然而，分离异黄酮对心血管疾病风险的脂质生物标志物的有益作用尚未得到证实。目的：目的是研究分离大豆异黄酮对心血管疾病风险代谢生物标志物的影响，包括血浆总胆固醇、HDL和LDL胆固醇；甘油三酯;脂蛋白(a);小密度LDL百分比；葡萄糖;非酯化脂肪酸；胰岛素;胰岛素抵抗的稳态模型评估。研究了所选基因(即雌激素受体a（Xbal和PvuII）、雌激素受体β (AluI)和雌激素受体β （cx) （Tsp5091）、内皮型一氧化氮合酶（Glu298Asp）、载脂蛋白E （Apo E2、E3和E4）、胆固醇酯转移蛋白（TaqIB）和瘦素受体（Gln223Arg））的单核苷酸多态性差异以及与雌酚产生有关的差异。设计：健康绝经后妇女（n = 117）参加了一项随机、双盲、安慰剂对照、交叉饮食干预试验。富含异黄酮（染料木黄酮与大豆黄酮的比例为1:1；50 mg/d）或安慰剂谷物棒被食用8周，在交叉之前有8周的洗脱期。结果：异黄酮对血脂、葡萄糖或胰岛素的血浆浓度没有显著的有益影响。雌激素受体0(cx) Tsp5091基因型AA组高密度脂蛋白胆固醇对异黄酮和安慰剂的反应有显著差异，但GG或GA组无显著差异。结论：异黄酮补充剂，在本研究中使用的形式和剂量下，对绝经后妇女心血管疾病风险的脂质或其他代谢生物标志物没有影响，但可能增加雌激素受体P基因多态性亚组中的高密度脂蛋白胆固醇。
Background: The hypocholesterolemic effects of soy foods are well established, and it has been suggested that isoflavones are responsible for this effect. However, beneficial effects of isolated isoflavones on lipid biomarkers of cardiovascular disease risk have not yet been shown.Objective: The objective was to investigate the effects of isolated soy isoflavones on metabolic biomarkers of cardiovascular disease risk, including plasma total, HDL, and LDL cholesterol; triacylglycerols; lipoprotein(a); the percentage of small dense LDL; glucose; nonesterified fatty acids; insulin; and the homeostasis model assessment of insulin resistance. Differences with respect to single nucleotide polymorphisms in selected genes [ie, estrogen receptor a (Xbal and PvuII), estrogen receptor beta (AluI), and estrogen receptor beta(cx) (Tsp5091), endothelial nitric oxide synthase (Glu298Asp), apolipoprotein E (Apo E2, E3, and E4), cholesteryl ester transfer protein (TaqIB), and leptin receptor (Gln223Arg)] and with respect to equol production were investigated.Design: Healthy postmenopausal women (n = 117) participated in a randomized, double-blind, placebo-controlled, crossover dietary intervention trial. Isoflavone-enriched (genistein-to-daidzein ratio of 2: 1; 50 mg/d) or placebo cereal bars were consumed for 8 wk, with a wash-out period of 8 wk before the crossover.Results: Isoflavones did not have a significant beneficial effect on plasma concentrations of lipids, glucose, or insulin. A significant difference between the responses of HDL cholesterol to isoflavones and to placebo was found with estrogen receptor 0(cx) Tsp5091 genotype AA, but not GG or GA.Conclusions: Isoflavone supplementation, when provided in the form and dose used in this study, had no effect on lipid or other metabolic biomarkers of cardiovascular disease risk in postmenopausal women but may increase HDL cholesterol in an estrogen receptor P gene-polymorphic subgroup.